Study | Study region | Study design | Study period | Sample size | Male/ Female | Cancer types | Treatment | Follow-up duration | Cut-off | Out-come | NOS |
---|---|---|---|---|---|---|---|---|---|---|---|
Zhang et al. 2022 [15] | Xi'an, China | R | 2010- 2017 | 615 | 469/146 | GC | Surgery | - | 39.8 | OS (M) DFS (M) | 8 |
Horino et al. 2022 [18] | Kumamoto, Japan | R | 04/2005–06/2019 | 813 | 464/349 | CRC | Surgery | - | 43.1/13.2e | OS (M) DFS (M) | 7 |
He et al. 2022 [19] | Nanjing, China | R | 01/2009–03/2016 | 358 | 284/74 | GC | Surgery | 101 (2–166)a | 40.5 | OS (M) | 6 |
Deng et al. 2022 [20] | Fuzhou, China | R | 01/2012–12/2016 | 360 | 194/166 | CRC | Surgery | 65 (3–110)a | 36.3 | OS (M) DFS (M) | 7 |
Tan et al. 2022 [23] | Nanning, China | R | 09/2013–07/2018 | 158 | 126/32 | EC | Surgery | - | 31.2 | OS (M) | 6 |
Xie et al. 2022 [25] | Nanning, China | R | 2012- 2014 | 662 | 408/254 | CRC | Surgery | 63 (1–80)a | 31.6/24.4e | OS (M) PFS (U) | 7 |
Kusunoki et al. 2022 [26] | Mie, Japan | R | 02/2005–11/2011 | 298 | 171/127 | CRC | Surgery | 39.7 ± 29.0c | 20.5 | OS (M) DFS (M) | 6 |
Pian et al. 2022 [17] | Suwon, Korea | R | 06/2009–06/2018 | 132 | 88/44 | CRC | Surgery | - | 70.4 | OS (M) DFS (U) | 7 |
Ruan et al. 2022 [24] | Multicenter, China | P | 06/2012–12/2019 | 691 | - | GM | Cancer Sarcopenia | 43.7b | 18.4 | OS (M) | 8 |
Wu et al. 2022 [16] | Fuzhou, China | R | 2016- 2019 | 97 | 58/39 | CC | Surgery | 20 (3–70)a | 31.8 | OS (M) DFS (M) | 6 |
Qian et al. 2022 [31] | Zhengzhou, China | R | 2017- 2020 | 65 | 55/10 | HCC | Camrel-izumab | - | 34.7 | OS (M) | 6 |
Chen et al. 2022 [32] | Fuzhou, China | R | 01/2013–04/2019 | 636 | 385/281 | CRC | Surgery | 59.3(40.6–80.4)d | 40.0 | OS (M) | 7 |
Tsai, et al. 2021 [22] | Taiwan, China | R | 01/2008–12/2017 | 372 | 336/36 | OCC | Surgery | 58.5 (2–126)a | 33.6 | OS (M) DFS (M) | 6 |
Yin et al. 2021 [21] | Mie, Japan | R | 1992–2011 | 620 | 424/196 | GC | Surgery | 52.8 ± 39.9c | 30.0 | OS (M) | 8 |
Shibutani et al. 2019 [29] | Osaka, Japan | R | 2008–2016 | 159 | 87/72 | CRC | Chemo-therapy | 21.6 (1.2–94.0)a | 28.9 | OS (M) | 7 |
Topkan et al. 2019 [28] | Adana, Turkey | R | 01/2007–12/2017 | 141 | 111/30 | PC | Chemor-adiotherapy | 14.4 (3.2–74.2)a | 25.3 | OS (U) PFS (U) | 7 |
Barth et al. 2019 [27] | Graz, Austria | R | 12/2003–10/2015 | 429 | 236/193 | PC | Surgery or chemotherapy | - | 43.5 | CSS (M) | 7 |
Feng et al. 2014 [30] | Hangzhou, China | R | 01/2006–12/2008 | 293 | 259/34 | EC | Surgery | - | 18.0 | CSS (M) | 6 |